Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-3405 in Participants With Sickle Cell Disease

NCT07187973 is registered in ClinicalTrials.gov with Disc Medicine, Inc as lead sponsor.

NCT NCT07187973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07187973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-3405 in Participants With Sickle Cell Disease
Lead sponsor
Disc Medicine, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
January 6, 2026
Completion date
October 31, 2027
Enrollment
24 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease